Skip to main content

Advertisement

Table 2 Baseline characteristics and demographics

From: Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Baseline Characteristics Exenatide (N = 2,316) Pooled Comparator (N = 1,629)
Gender, M/F (%) 56/44 53/47
Race (%)   
   Caucasian 64 65
   Black 6 4
   Hispanic 11 10
   Asian 19 20
   Other 1 1
Age (years) 56 ± 10 56 ± 10
   ≥65 years (%) 21 20
Duration of Diabetes (years) 8 ± 6 8 ± 6
   ≥10 years (%) 32 35
Weight (kg) 89.1 ± 20.3 87.8 ± 19.8
Body Mass Index (BMI [kg/m 2 ]) 31.5 ± 5.6 31.3 ± 5.4
   BMI <30 kg/m2 (%) 44 45
   BMI ≥30 kg/m2 (%) 56 55
HbA 1c (%) 8.33 ± 1.06 8.38 ± 1.07
Systolic Blood Pressure (SBP [mm Hg]) 131 ± 4 132 ± 5
Diastolic Blood Pressure (DBP [mm Hg]) 79 ± 2 79 ± 1
Heart Rate (beats per minute) 75 ± 9 75 ± 9
Renal Function Impairment* (%)   
   None 86 86
   Mild 13 14
   Moderate 1 1
  1. Data are mean ± SD unless otherwise noted. Percentages may not add to 100 due to rounding
  2. * Renal function is defined based on creatinine clearance (CrCl) as calculated by the Cockcroft-Gault equation: normal, CrCl >80 mL/min; mild impairment, CrCl >50-80 mL/min; moderate impairment, CrCl >30-50 mL/min